Antihypertensive Drugs Market

Hypertension also called as high blood pressure, is a chronic condition which occurs when the blood pressure in the arteries is continuously elevated. Long-term high blood pressure is a major risk factor for coronary artery disease, stroke, heart failure, vision loss, atrial fibrillation, peripheral vascular disease, chronic kidney disease, and dementia, among others. High blood pressure is classified as either primary hypertension and secondary hypertension. The increasing prevalence of hypertension is expected to contribute to the growth of the market over the forecast period.

The global antihypertensive drugs market is expected to reach USD 41,123.2 million by 2023 from USD 34,843.6 million in 2017 and is expected to register a CAGR of 2.67% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with a 36.6% share, followed by Europe and Asia-Pacific with shares of 28.2% and 22.8%%, respectively.

The market has been segmented based on therapeutic class, type, distribution channel, and region.

The global antihypertensive drugs market on the basis of therapeutic class has been segmented into diuretics, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), calcium channel blockers, beta-adrenergic blockers, renin inhibitors, vasodilators, and others. The diuretics segment accounted for the largest market share of 28% in 2017, with a market value of USD 9920.6 million, which is projected to register a CAGR of 2.85% during the forecast period.

The market based on type has been segmented into primary hypertension and secondary hypertension. The primary hypertension segment accounted for the largest market share of 86% in 2017, with a market value of USD 30,075.6 million, which is projected to register a CAGR of 2.53% during the forecast period.

Global antihypertensive drugs market, on the basis of distribution channel, has been segmented into retail pharmacy, online pharmacy, E-commerce websites and online drug stores, and others. The retail pharmacy segment accounted for the largest market share of 45% in 2017, with a market value of USD 15,805.7 million in 2017, which is projected to register a CAGR of 2.67% over the assessment period.